Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin by Bedendi, I et al.
www.elsevier.com/locate/ejphar
European Journal of Pharmacology 476 (2003) 87–95Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl
ghrelin and des-Gln14-ghrelin
Ivano Bedendia,b, Giuseppe Alloattia,b,*, Andrea Marcantonib, Daniela Malanb,
Filomena Catapanoc, Corrado Ghe´c, Romano Deghenghid,
Ezio Ghigod, Giampiero Mucciolic
a Istituto Nazionale per la Fisica della Materia, University of Turin, Turin, Italy
bDepartment of Animal and Human Biology, University of Turin, Turin, Italy
cDivision of Pharmacology, Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, Turin, Italy
dDivision of Endocrinology, Department of Internal Medicine, University of Turin, Turin, ItalyReceived 20 March 2003; received in revised form 2 July 2003; accepted 8 July 2003Abstract
The mechanisms underlying the cardiac activities of synthetic growth hormone secretagogues (GHS) are still unclear. The natural ligand
of the GHS receptors, i.e. ghrelin, classically binds the GHS receptor and exerts endocrine actions in acylated forms only; its cardiovascular
actions still need to be investigated further. In order to clarify these aspects, we studied the effects of either the synthetic peptidyl GHS
hexarelin (1 AM), or the natural ghrelin (50 nM) and the endogenous ghrelin derivatives des-Gln14-ghrelin (1–100 nM) and des-octanoyl
ghrelin (50 nM), on the tension developed by guinea pig papillary muscle and on L-type Ca2 + current (ICa) of isolated ventricular cells. The
binding of these molecules to ventricular cell membrane homogenates was also studied. We observed that all peptides reduced the tension
developed at low frequencies (60–120 beats/min) in a dose-dependent manner. No alteration in cardiac contractility was induced by des-
Gln14-ghrelin or des-octanoylated ghrelin when the endocardial endothelium had been removed or after cyclooxygenase blockade.
Pretreatment with tyramine (2 AM) had no effect on the inotropic response induced by des-Gln14-ghrelin. No significant effect on ICa of
isolated ventricular cells was observed in the presence of des-Gln14-ghrelin (100 nM). The order of potency on the tension of papillary
muscle was: des-octanoyl ghrelin>ghrelin = des-Gln14-ghrelin>hexarelin. This gradient of potency was consistent with the binding
experiments performed on ventricular membranes where either acylated or unacylated ghrelin forms, and hexarelin, recognized a common
high-affinity binding site. In conclusion, ghrelin, des-Gln14-ghrelin and des-octanoyl ghrelin, show similar negative inotropic effect on
papillary muscle; as des-octanoyl ghrelin is peculiarly devoid of any GH-releasing activity, the cardiotropic action of these molecules is
independent of GH release. The binding studies and the experiments performed both on the isolated cells and on papillary muscle after
endothelium removal or cyclooxygenase blockade indicate that the cardiotropic action of natural and synthetic ghrelin analogues reflects the
interaction with a novel GHS receptor (peculiarly common for ghrelin and des-octanoyl ghrelin), leading to release of cyclooxygenase
metabolites from endothelial cells, as indicated by direct measurement of prostacyclin metabolite 6-keto-PGF1a.
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GH and IGF-1 excess or deficit are generally associated
with deranged myocardial structure and performance (Bro-
glio et al., 1999; Osterziel et al., 2000).
Cardiotropic activities are also exerted by other molecules
known as GH secretagogues (GHS) that are distinct entities
from GHRH, the endogenous hypophysiotropic neurohor-
mone stimulating somatotroph secretion (Ghigo et al., 1997;
Mu¨ller et al., 1999). GHS were discovered as a family of
non-natural peptidyl and non-peptidyl molecules able to
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protein coupled receptor, namely GHS type 1a receptor, that
is different from the GHRH-receptor (Smith et al., 1997;
Muccioli et al., 1998, 2002). Theoretically, GHS would
therefore influence cardiac structure and function via en-
hanced GH and IGF-I secretion. However, it has also been
demonstrated that these molecules, at least the peptidyl ones,
exert also direct and GH-independent cardiac actions. This is
suggested by the observations that these effects occur also in
hypopituitaric patients (Muccioli et al., 2000) and that are not
exerted by GHS analogues (i.e. EP-51389) with strong GH-
releasing activity, but lacking cardiac binding sites (Locatelli
et al., 1999; Mu¨ller et al., 2002). In particular, peptidyl GHS,
such as hexarelin, improve the post-ischemic recovery of
hearts of either aged or GH-deficient rats (Locatelli et al.,
1999) and increase left ventricular ejection in patients with
severe GH-deficiency (Bisi et al., 1999; Imazio et al., 2002).
A stimulatory effect on cell proliferation (Pettersson et al.,
2002) and an antiapoptotic action (Filigheddu et al., 2001) of
GHS on the cardiomyocyte cell line H9c2 have also been
shown. The natural ligand of the GHS type 1a receptor has
more recently been discovered as a gastric-derived hormone
named ghrelin (Kojima et al., 1999). It is an acyl-peptide
consisting of 28 amino acids and esterified with octanoic
acid on Ser3, though a form of 27 amino acids, des-Gln14-
ghrelin (resulting from alternative splicing of the same gene)
has also been isolated (Hosoda et al., 2000a). Both exist in
either acylated and, more abundantly, non-acylated form
(Hosoda et al., 2000b), but the latter have been shown
inactive in term of endocrine activities (Kojima et al.,
2001). They do not stimulate GH secretion in vivo (Torsello
et al., 2002) because do not bind and activate the GHS type
1a receptor (Bednarek et al., 2001) neither displace radio-
labelled ghrelin from its hypothalamo-pituitary binding sites
(Muccioli et al., 2001; Torsello et al., 2002). The gastric
peptide ghrelin is endowed with a strong stimulatory effect
on GH release, gastric acid secretion and gut motility in rats
and humans (Kojima et al., 2001). However, many recent
studies have demonstrated that ghrelin is much more than a
natural GH secretagogue and that its biological actions are
not confined to the pituitary or to the gastro-intestinal tract.
In fact, it has been reported that ghrelin increases food
intake, adiposity and causes a positive energy balance, as
well as modulates glucose metabolism and cell growth in
non-tumoural and neoplastic tissues (Muccioli et al., 2002).
In addition, as a result of studies conducted in vitro and in
vivo, it has been already reported that ghrelin not only exerts
cardiovascular effects in humans (Muccioli et al., 2000;
Okumura et al., 2002; Nagaya and Kangawa, 2003), but it
has also been demonstrated that ghrelin does not share all
cardiac activities exerted by synthetic GHS (Torsello et al.,
2003). Interestingly, besides GHS type 1a receptor mRNA
expression (Nagaya and Kangawa, 2003) and specific bind-
ing sites labelled by [125I]His9-ghrelin (Katugampola et al.,
2001), animal and human myocardium possess also GHS
receptors that are specific for peptidyl GHS and which donot recognise ghrelin or the non-peptidyl GHS, MK-0677
(Bodart et al., 1999; Papotti et al., 2000). The recent finding
that H9c2 cardiomyocytes do not express GHS type 1a
receptor, but have high affinity binding sites, common for
ghrelin and des-acyl ghrelin, involved in mediating their
antiapoptotic activity, provides further support to the hy-
pothesis that multiple ghrelin and GHS receptors exist in the
cardiovascular system (Baldanzi et al., 2002). Each receptor
may then contribute independently to the wide array of
cardiovascular activities induced by synthetic GHS, ghrelin
and endogenous ghrelin-derived molecules (Muccioli et al.,
2000, 2002; Torsello et al., 2003).
In order to clarify the mechanisms underlying the
cardiac activities of ghrelin and to verify whether its
different molecular forms are cardioactive or not, we have
studied the effects of ghrelin (50 nM), des-Gln14-ghrelin
(1–100 nM) and des-octanoyl ghrelin (50 nM), as well as
of the synthetic peptidyl GHS hexarelin (1 AM), on the
tension developed by guinea pig papillary muscle, a model
that shows a biphasic force–frequency relationship similar
to that reported for human cardiac muscle (Brixius et al.,
1999). The effects of ghrelin and its derivatives on L-type
calcium current (ICa) of isolated ventricular cells and the
binding of all these molecules to ventricular cell membrane
homogenates have also been studied.2. Materials and methods
2.1. Materials
Human ghrelin (Gly-Ser-Ser-(O n-octanoyl)-Phe-Leu-
Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-
Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-NH2) and
des-octanoyl ghrelin were purchased from Phoenix
Pharmaceuticals (Belmont CA, USA), whereas des-Gln14-
ghrelin was both from Tocris (Pallwin, MO, USA) and
Phoenix Pharmaceuticals, Tyr4-ghrelin, Tyr4-des-octanoyl
ghrelin, and hexarelin (His-D-2Me-Trp-Ala-Trp-D-Phe-Lys-
NH2) were purchased from Neosystem (Strasbourg,
France). [125I]Tyr4-ghrelin (1800–2100 Ci/mmol) and
[125I]Tyr4-des-octanoyl ghrelin (1700–2000 Ci/mmol)
were iodinated using a lactoperoxidase method and puri-
fied by reverse-phase high-performance liquid chromatog-
raphy, as previously described (Muccioli et al., 2001). The
release of PGI2 was measured by evaluating the concen-
tration of 6-keto-PGF1a in perfusate samples, with an
enzymeimmunoassay kit (Amersham International, UK).
Solutions used in the experiments on papillary muscles
or on isolated ventricular cells were freshly prepared as
previously described (Bedendi et al., 2001).
2.2. Animals and tissue preparation
Animal care, sacrifice and experiments were conducted
according to the European Community guidelines for care
Fig. 1. Effects of the synthetic peptide hexarelin (1 AM) (A) and of the
endogenous peptide ghrelin (50 nM) (B) on isolated papillary muscle. The
peak tension was recorded from papillary muscles stimulated at different
beating frequencies in control conditions (5) and after treatment with
hexarelin (n, n= 4), or ghrelin (., n= 4). Data are expressed as the
meanF S.E.M. % of the values measured at 120 beats/min before
treatment. Statistical analysis was performed between data recorded at
each frequency, before and after application of the drug (ANOVA followed
by Student–Newman–Keuls test; *P < 0.05; **P< 0.01; ***P< 0.001).
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ethical committee. Young adult guinea pigs of either sex
were anaesthetized with ether and killed by stunning and
cervical dislocation.
Papillary muscle or isolated ventricular cells were used to
study the effects of hexarelin and different ghrelin mole-
cules on contractility or calcium current. Binding studies on
ventricular tissue homogenates of male guinea pigs were
also performed.
2.3. Isolated papillary muscle and contractility
determination
As previously detailed (Bedendi et al., 2001), papillary
muscles were driven at various frequencies (from 60 to 320
beats/min). Peak tension, the maximum rate of rise ( + dT/
dtmax) and of fall ( dT/dtmax) of developed tension were
acquired, recorded and measured by a Power Mac computer,
using the Labview Software (National Instruments, Texas,
USA).
The effects of the following drugs were tested: hexarelin
(1 AM), ghrelin and des-octanoyl ghrelin (50 nM), des-
Gln14-ghrelin (1–100 nM). Endocardial endothelium was
removed as previously described (Bedendi et al., 2001). To
study the role of cyclooxygenase metabolites and of the
possibly released catecholamines by nerve endings, papil-
lary muscles were pretreated with indomethacin (1 AM) or
tyramine (2 AM) for 30 min, respectively.
2.4. ICa measurements in isolated ventricular cells
Ventricular myocytes were obtained from hearts of adult
guinea pig by enzymatic dissociation using methods de-
scribed previously (Bedendi et al., 2001). To measure ICa,
the cell was depolarised every 5 s from  100 to  40 mV
for 50 ms, to inactivate both fast Na current and T-type
calcium current, and from there for 300 ms to + 10 mV, that
is the potential at which ICa is maximal. All control and
analysis of the experiments were performed with the Axo-
data and Axograph-4 programs (Axon Instruments, CA,
USA) on PowerMac computers (Apple Computer, CA,
USA). The experiments were performed at 35 jC under
thermostatic control.
2.5. Ghrelin binding assay
Binding of ghrelin and des-octanoyl ghrelin to tissue
membranes was studied using as radioligands [125I]Tyr4-
ghrelin and [125I]Tyr4-des-octanoyl ghrelin. Tyr4-ghrelin has
been reported to have the same GH-releasing potency of
native ghrelin in rats and to be a reliable probe for labelling
ghrelin receptors in the hypothalamus and pituitary gland
(Muccioli et al., 2001; Torsello et al., 2002). To perform
binding studies, the atria were removed and ventricles were
minced in small pieces and stored at  40 jC. Afterwards,
the membrane fractions (30,000 g pellet) were preparedfrom frozen pieces of ventricular myocardium using the
method previously described for brain and pituitary gland
(Muccioli et al., 2001). Membranes were resuspended in ice-
cold buffer (50 mM Tris–HCl, 2.5 mM EGTA, 0.002%
bacitracin, pH 7.4) and immediately used to determine
protein content by the method of Lowry and for binding
studies. For saturation binding studies, tissue membranes
(corresponding to 100 Ag protein) were incubated in tripli-
cate at 23 jC for 2 h under constant shaking with increasing
concentrations (0.035–3 nM) of [125I]Tyr4-ghrelin or
[125I]Tyr4-des-octanoyl ghrelin in a final volume of 0.5 ml
assay buffer (50 mM Tris–HCl, 2.5 mM EGTA, 0.002%
bacitracin, 0.1% bovine serum albumin, pH 7.4). Parallel
incubations, where 2.0 AM unlabelled ghrelin or des-octa-
noyl ghrelin was also present, were used to determine
nonspecific binding, which was subtracted from total bind-
ing to yield specific binding values. The binding reaction
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scribed (Muccioli et al., 1998, 2001) and the radioactivity
remaining bound to the filters was measured by a Packard
gamma counter A5003. Specific binding was expressed as
fmol/mg protein. Saturation isotherms were transformed
using the method of Scatchard and the maximal number of
binding sites (Bmax) and the dissociation constant (Kd) were
calculated with the GraphPAD Prism 3 program (GraphPAD
Software, San Diego, CA, USA). To show binding site
specificity, increasing concentrations ghrelin, des-Gln14
ghrelin, des-octanoyl ghrelin and hexarelin were tested in
competition assays with [125I]Tyr4-ghrelin or [125I]Tyr4-des-
octanoyl ghrelin and the IC50 values for the various com-
petitors were calculated by iterative nonlinear curve fitting
program.
2.6. Statistical analysis
All results are expressed as mean valuesF S.E.M. Sta-
tistical analysis was carried out with one-way analysis of
variance followed by Student’s two-tailed t-test or New-
man–Keuls multiple range test depending on the experi-
ments. P < 0.05 was chosen as level of significance. The
number of experiments is indicated by n.3. Results
3.1. Contractile effect on isolated papillary muscle
In previous experiments, we observed that hexarelin
modifies the force–frequency relationship in rat papillary
muscle, reducing the tension developed at low frequencies,
while at higher frequencies contractile force was unaltered
(Bedendi et al., 2001). We observed that, similarly to the
rat, also in the guinea pig papillary muscle hexarelin (1
AM) reduces the tension developed at low frequencies (60–
120 beats/min), while the tension at higher frequencies
(150–320 beats/min) is unaffected (Fig. 1A; at 120 beats/Table 1
Effect of synthetic hexarelin and endogenous peptides ghrelin, des-octanoyl gh
(control), or pretreated with Triton X-100 or indomethacin, at different beating fr
(Beats/min) 60 80
Control 69.8F 3.9 78.0F 1.8
Hexarelin 40.4F 5.9* 48.1F 2.9*
Ghrelin 44.7F 3.1* 56.4F 2.8
Des-octanoyl ghrelin 33.5F 4.1y 48.0F 5.3 w
Des-Gln14-ghrelin 53.8F 3.9 66.1F 5.6
Triton 66.4F 4.9 73.0F 5.2
Triton + des-octanoyl ghrelin 64.8F 6.2 70.8F 6.1
Triton + des-Gln14-ghrelin 55.2F 3.1 64.1F 2.7
Indomethacin 60.9F 2.5 80.0F 7.6
Indomethacin + des-octanoyl ghrelin 54.7F 6.2 74.7F 5.5
Values are expressed as the meanF S.E.M. % of the value at 120 beats/min befor
same as indicated in Figs. 1 and 2. Statistical analysis was performed between
(ANOVA followed by Student–Newman–Keuls test; *P < 0.05; wP < 0.01; yP< 0min, contractile force = 64.7F 10.9% of the control, n = 4).
The negative inotropic effect induced at low beating
frequencies was accompanied by a decrease of both + dT/
dtmax (all + dT/dtmax values are summarized in Table 1)
and  dT/dtmax. Like hexarelin, the endogenous ligands for
GHS receptors, ghrelin and des-Gln14-ghrelin, reduced
peak tension (at 120 beats/min, 60.8F 7.6 and 75.4F 9.1%
of the control; n = 5 and 6, respectively; Figs. 1B and 2A), as
well as + dT/dtmax and  dT/dtmax at low stimulation rates.
Guinea pig papillary muscle was more sensitive to the
action of both ghrelin and des-Gln14-ghrelin, in comparison
with hexarelin. Indeed, the effects exerted by addition of 50
nM ghrelin or des-Gln14-ghrelin were comparable to those
caused by a 20-fold higher concentration of hexarelin.
Dose– response experiments, performed on papillary
muscles stimulated at constant frequency (120 beats/min),
showed that 50 nM des-Gln14-ghrelin was the half-maximal
effective concentration, the tensions measured being:
101.6F 1.3%, 91.9F 3.7%, 85.7F 5.2% and 84.1F1.9%,
at 0.5 (n = 3), 5 (n = 4), 50 (n = 5) and 100 nM (n = 5),
respectively (all values expressed as a percentage of the
control). Papillary muscles treated with tyramine, to exclude
any interference by catecholamines released from nerve
endings, showed a negative inotropic response to des-
Gln14-ghrelin (50 nM), which was superimposable to that
observed in untreated preparation (at 120 beats/min,
78.6F 19.1%, n = 3, vs. 75.4F 9.1%, n= 6).
In order to verify if also des-octanoyl ghrelin, the
form of ghrelin inactive on GH release was able to
modulate inotropism, we compared its effect to those
exerted by ghrelin and des-Gln14-ghrelin. Surprisingly, we
observed a significant response to this non-acylated
peptide, which caused a negative inotropic effect extend-
ed also to higher frequencies (150–240 beats/min) (Fig.
2A; at 120 beats/min the tension was 51.0F 11.8% of
the control, n = 4).
To study the role of endocardial endothelium and of
prostacyclin in the inotropic effect induced by these pep-
tides, we performed further experiments on guinea pig-relin and des-Gln14-ghrelin on + dT/dtmax, in papillary muscles untreated
equencies (60–200 beats/min)
120 150 171 200
100.0 102.5F 1.5 111.1F 6.6 105.4F 11.2
67.6F 11.9 84.0F 3.5 89.9F 2.3 90.8F 6.2
76.85F 11.9 79.7F 7.3* 90.6F 7.2* 91.5F 8.6*
64.8F 17.7 73.9F 7.4 80.9F 12.5 70.7F 3.5
84.5F 8.7 86.6F 2.3 94.8F 3.6 99.5F 7.4
100.0 118.6F 4.3 132.2F 5.9 140.4F 10.6
98.9F 12.3 111.3F 8.0 128.5F 12.8 141.6F 15.5
85.2F 17.7 100.7F 6.2 112.4F 8.0 127.6F 11.4
100.0 98.4F 5.9 98.8F 4.3 95.1F 4.4
104.4F 14.3 99.9F 7.6 116.2F 5.0 103.1F 7.1
e treatment. Concentration of the drugs and number of experiments are the
data recorded at each frequency, before and after application of the drug
.001).
Fig. 2. Relationship between beating frequency and peak tension developed
by papillary muscles: (A) perfused with Tyrode solution alone (5, n= 12),
containing 50 nM des-octanoyl ghrelin (o, n= 6) or 50 nM des-Gln14-
ghrelin (x, n= 6); (B) deprived of endocardial endothelium perfused with
Tyrode solution alone ( w , n= 12), containing 50 des-octanoyl ghrelin (o,
n = 6) or 50 nM des-Gln14-ghrelin (x, n = 6); (C) pretreated with
indomethacin (1 AM), before (5) and after treatment with 50 nM des-
octanoyl ghrelin (o, n= 4). Values are expressed as meanF S.E.M.
Statistical significance: *P< 0.05; **P < 0.01; ***P < 0.001.
Fig. 3. Representative saturation isotherms (A) and Scatchard plot (B) of
[125I]Tyr4-ghrelin binding to membranes from ventricular myocardium of
guinea pig. Experiments were performed by incubating a fixed amount of
membrane protein (100 Ag/tube) with increasing concentrations of radio-
labelled ghrelin (total binding, .) or plus 2.0 AM unlabelled ghrelin to
define nonspecific binding (z). Specific binding values (o) were obtained
by subtracting nonspecific binding from total binding. The saturation curve
of specific binding was analyzed by Scatchard analysis in order to calculate
the maximal binding capacity (Bmax) and the dissociation constant (Kd).
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pretreated with indomethacin (1 AM). Both treatments did
not significantly alter the shape of the force–frequency
relationship. As shown in Fig. 2B, removal of endocardialendothelium markedly reduced the inotropic response of
guinea pig papillary muscle to both des-Gln14-ghrelin and
des-octanoyl ghrelin (89.4F 12.8% and 82.0F 6.7%; n = 6
and 5, respectively). A similar result was obtained in
papillary muscles in which des-octanoyl ghrelin was applied
after cyclooxygenase blockade (Fig. 2C; 99.6F 13.7%,
n = 4).
The hypothesis that the inotropic effect of ghrelin is
mainly due to PGI2 released from endothelial cells, was
further supported by direct measurement of the prostacyclin
metabolite, 6-keto-PGF1a. In our preparations, baseline
production of 6-keto-PGF1a was 52.5F 3.5 pg/ml; des-
octanoyl ghrelin (50 nM) induced a significant enhancement
of 6-keto-PGF1a release (130.7F 4.9%), which was com-
pletely blocked by 1 AM indomethacin (86.0F 2.3%).
Fig. 4. Competition for [125I]Tyr4-ghrelin binding to membranes of
ventricular myocardium by ghrelin, des-Gln14-ghrelin, des-octanoyl ghrelin
and hexarelin. Binding assays were conducted as described in Materials and
methods. The ordinate represents binding as a percentage of control
(specific binding in the absence of unlabelled competitor). Each point
represents the meanF S.E.M. of three separate experiments.
Fig. 5. Representative saturation isotherms (A) and Scatchard plot (B) of
[125I]Tyr4-des-octanoyl ghrelin binding to membranes from ventricular
myocardium of guinea pig. Experiments were performed by incubating a
fixed amount of membrane protein (100 Ag/tube) with increasing
concentrations of radiolabelled des-octanoyl ghrelin (total binding, .) or
plus 2.0 AM unlabelled des-octanoyl ghrelin to define nonspecific binding
(z). Specific binding values (o) were obtained by subtracting nonspecific
binding from total binding. The saturation curve of specific binding was
analyzed by Scatchard analysis in order to calculate the maximal binding
capacity (Bmax) and the dissociation constant (Kd).
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After the patch membrane was broken to achieve the
whole-cell condition, the isolated cells were allowed to
equilibrate for at least 5 min. The application of des-Gln14-
ghrelin at a concentration (100 nM) able to reduce signifi-
cantly the contractile force developed by papillary muscle,
did not modify the L-type calcium current on isolated
ventricular cells. In eight cells, ICa was  1.40F 0.16 nA
in control conditions, and  1.36F 0.15 nA in the presence
of des-Gln14-ghrelin ( p = n.s.). However, the fact that in the
same cells ICa promptly increased after application of iso-
proterenol (1 AM), suggests that they were still responsive to
stimulation of membrane receptors.
3.3. Binding of [125I]Tyr4-ghrelin and [125I]Tyr4-des-
octanoyl ghrelin to membranes from ventricular
myocardium
In order to investigate the identity of the receptor mediat-
ing the effects of ghrelin and des-octanoyl ghrelin on guinea
pig heart, we have performed binding studies of [125I]Tyr4-
ghrelin and [125I]Tyr4-des-octanoyl ghrelin to membranes of
guinea pig ventricular myocardium. Experiments using in-
creasing concentrations of [125I]Tyr4-ghrelin revealed the
presence of a saturable specific binding (associated with a
low nonspecific binding) that increased linearly with the
radioligand concentrations (Fig. 3A). Scatchard analysis of
the specific binding data (Fig. 3B) demonstrated the existence
of a single class of binding sites with a dissociation constant
(Kd) of 0.51F 0.06 nM and a maximal binding capacity
(Bmax) of 10.9F 1.8 fmol/mg of protein (n = 4). Unlabelled
ghrelin, des-Gln14 ghrelin, hexarelin) and, surprisingly, des-
octanoyl ghrelin, an endogenous ghrelin precursor which isunable to bind the hypothalamo-pituitary receptor for GH
secretagogues (Muccioli et al., 2001; Torsello et al., 2002)
competed with [125I]Tyr4-ghrelin for cardiac binding sites
(Fig. 4). The IC50 values, all expressed as nM concentrations,
were 8.1F 0.9 for ghrelin, 7.4F 0.4 for des-Gln14 ghrelin,
12.5F 1.7 for des-octanoyl ghrelin and 20.8F 2.3 for hex-
arelin (meanF S.E.M. of three separate experiments).
Experiments using increasing concentrations of [125I]Tyr4-
des-octanoyl ghrelin also provided consistent evidence of a
saturable specific binding in ventricular myocardium of
guinea pig (Fig. 5A). Scatchard analysis demonstrated the
Fig. 6. Competition for [125I]Tyr4-des-octanoyl ghrelin binding to
membranes of ventricular myocardium by des-octanoyl ghrelin, ghrelin,
des-Gln14-ghrelin and hexarelin. Binding assays were conducted as
described in Materials and methods. The ordinate represents binding as a
percentage of control (specific binding in the absence of unlabelled
competitor). Each point represents the meanF S.E.M. of three separate
experiments.
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of Bmax (12.2F 1.4 fmol/mg protein, n = 4) and Kd (0.74F
0.12 nM, n= 4), very close to those detected by radio-
labelled ghrelin (Fig. 5B). Both unlabelled ghrelin and des-
octanoyl ghrelin, as well as des-Gln14-ghrelin and hexar-
elin competed with [125I]Tyr4-des-octanoyl ghrelin for
binding sites (Fig. 6). IC50 values, all expressed as nM
concentrations (meanF S.E.M. of three separate experi-
ments) of 10.4F 0.8 for des-octanoyl ghrelin, 12.2F 1.8
for ghrelin, 16.5F 0.8 for des-Gln14-ghrelin and 22.0F 2.1
for hexarelin.4. Discussion
The results of present study demonstrate that ghrelin,
des-Gln14-ghrelin or des-octanoyl ghrelin, as well as hexar-
elin, a synthetic peptidyl growth hormone secretagogue
(GHS), all show similar negative inotropic effect on the
guinea pig papillary muscle. Interestingly, the most signif-
icant influence on contractility of the papillary muscle was
exerted by des-octanoyl ghrelin, an unacylated form devoid
of any endocrine action (Kojima et al., 2001; Torsello et al.,
2002) because this form, unlike octanoylated ghrelin and
des-Gln14-ghrelin (Hosoda et al., 2000a), is unable to bind
the classical GHS type 1a receptor (Bednarek et al., 2001).
The binding studies performed here with either acylated and
unacylated ghrelin demonstrated that there is a specific
receptor recognized by all ghrelin forms and by hexarelin
as well; these findings therefore indicate the existence of a
cardiac non-GHS type 1a receptor. No change in cardiac
contractility was induced by either acylated or unacylated
ghrelin when the endocardial endothelium had been re-moved or after pretreatment with indomethacin, suggesting
that these effects are mediated by cyclooxygenase metabo-
lites produced by endothelial cells. In contrast, ghrelin did
not modify L-type calcium current of isolated ventricular
cells and this finding further supports the hypothesis that the
effects of ghrelin are mainly due to endothelium-released
prostaglandins.
The existence of GH-independent cardiotropic activities
of GHS had also been demonstrated by previous works
(Locatelli et al., 1999; Muccioli et al., 2000) showing that
these effects also occur in hypopituitaric patients (Bisi et al.,
1999) and that they are not produced by GHS analogues
(EP-51389) with strong GH-releasing activity, but lacking
cardiac binding sites (Locatelli et al., 1999; Mu¨ller et al.,
2002). In particular, peptidyl GHS, such as hexarelin,
improve the post-ischemic recovery of hearts from either
aged or GH-deficient rats (Locatelli et al., 1999; Mu¨ller et
al., 2002) and increase left ventricular ejection in patients
with severe GH deficiency (Bisi et al., 1999; Imazio et al.,
2002). An antiapoptotic action of synthetic GHS has also
been shown on H9c2 cardiomyocytes (Filigheddu et al.,
2001). Moreover, we have previously reported that the
peptidyl GHS hexarelin has negative inotropic effect on
rat papillary muscle (Bedendi et al., 2001). We have now
shown that the same action of hexarelin is exerted by an
endogenous ligand of GHS type 1a receptor, such as ghrelin,
a 28 amino acid gastric peptide with an octanoyl modifica-
tion at Ser3 essential for the hormone’s binding and bioac-
tivity (Kojima et al., 2001). The same action was found to
be exerted by des-Gln14-ghrelin, another natural acylated
form of ghrelin derived from an alternative splicing of the
ghrelin gene also capable of binding the GHS type 1a
receptor (Hosoda et al., 2000a). However, we have now
found unexpectedly that non-acylated ghrelin was able to
exert the same action at even greater extent than the acylated
forms of ghrelin, even though unacylated ghrelin is gener-
ally assumed to be devoid of biological activity (Kojima et
al., 2001), as it cannot bind and activate the GHS type 1a
receptor (Bednarek et al., 2001). Although GHS type 1a
receptor expression at the myocardial level has been dem-
onstrated (Nagaya and Kangawa, 2003), the existence of
GHS receptor subtypes in the heart has been already shown
(Muccioli et al., 2000, 2002). At the myocardial level and
within the vasculature, a receptor that binds synthetic
peptidyl GHS only, but not ghrelin or non-peptidyl GHS,
has been demonstrated (Bodart et al., 1999; Papotti et al.,
2000). In this present work, we have demonstrated the
existence of a cardiac receptor that binds a peptidyl GHS,
namely hexarelin, as well as ghrelin either in acylated or
unacylated form. This is therefore another GHS receptor
subtype that could well mediate the inotropic action of all
these molecules on the papillary muscle of both the guinea
pig and the rat. It is important to note that the existence of a
GHS receptor subtype able to bind either acylated or
unacylated ghrelin and hexarelin had been already demon-
strated in cultured cardiomyocytes and endothelial cells
I. Bedendi et al. / European Journal of Pharmacology 476 (2003) 87–9594(Baldanzi et al., 2002), as well as in neoplastic breast
carcinoma cell lines (Cassoni et al., 2001). On the cardio-
myocytes, this receptor is probably involved in mediating
the cytoprotective effect exerted by ghrelin (in acylated or
unacylated form) and by hexarelin (Baldanzi et al., 2002).
In vivo studies have demonstrated that ghrelin exerts
cardiac actions also in humans (Okumura et al., 2002;
Nagaya and Kangawa, 2003). Ghrelin administration indu-
ces hemodynamic effects in man either in normal subjects or
in patients with dilated cardiomyopathy, reducing cardiac
afterload and increasing cardiac output, without an increase
in heart rate (Nagaya and Kangawa, 2003). In addition,
ghrelin is an effective endothelium-independent vasodilata-
tor of the long-lasting constrictor endothelin-1 in human
arteries (Wiley and Davenport, 2002) and acts, at least in
part, on the central nervous system decreasing arterial
pressure and renal sympathetic activity in conscious rabbits
(Matsumura et al., 2002). However, it is not mandatory that
ghrelin and synthetic GHS share all the cardiotropic actions,
as indicated by recent data showing that, differently from
hexarelin, ghrelin exert minimal protective action against
cardiac ischemia in hypophysectomized rats (Torsello et al.,
2003). Some different cardiotropic actions exerted by nat-
ural and synthetic GHS could be well explained by the
existence of various GHS receptor subtypes (see above).
Regarding the negative inotropic effect demonstrated in
the present and a previous study (Bedendi et al., 2001), it is
important to note that all ghrelin forms and the peptidyl
GHS hexarelin loose their activity when tested on papillary
muscles deprived of endocardial cells or in isolated ventric-
ular cells. These findings strongly indicate a major role of
endothelial cells in mediating GHS inotropic action. This
assumption is strengthened by a previous observation
obtained studying the effect of hexarelin on the rat papillary
muscle (Bedendi et al., 2001). Endothelial cells synthetize
and release many potential mediators, among these prosta-
cyclins (Mebazaa et al., 1993). In agreement with the
hypothesis that prostacyclin mediates the inotropic effect
of GHS, in our study, a pretreatment of papillary muscle
with indomethacin completely blocked the action of des-
octanoyl ghrelin. The involvement of prostacyclin was also
confirmed by direct detection of increased amounts of 6-
keto-PGF1a released after des-octanoyl ghrelin application.
On the other hand, ghrelin effects are neither accompanied
by alterations of plasma cyclic guanosine 3,5-monophos-
phate level nor inhibited by pretreatment with nitric oxide
synthase inhibitors, suggesting NO-independent mechanism
of action (Okumura et al., 2002). It has been reported that
ghrelin may modulate sympathetic nerve activity (Matsu-
mura et al., 2002). However, we observed that the negative
inotropic effect of des-octanoyl ghrelin was unaltered after
pretreatment with tyramine. This finding excludes a relevant
role of endogenous catecholamines released by nerve end-
ings within cardiac tissue.
In conclusion, ghrelin either in acylated or unacylated
form, as well as peptidyl GHS show similar inotropic effecton guinea pig papillary muscle. The cardiotropic action of
natural and synthetic ghrelin analogues probably reflects the
interaction with a novel GHS receptor (peculiarly common
for ghrelin and des-octanoyl ghrelin) and is mediated by
cyclooxygenase metabolites produced by endothelial cells.Acknowledgements
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